Clinical trial NCT04118088: A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula
Official title: Postauthorization Safety Study of the Long-Term Safety and Efficacy of Repeat Administration of Darvadstrocel in Patients With Crohn's Disease and Complex Perianal Fistula
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Crohn's Disease
Complex Perianal Fistula
Keywords: Drug therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
Collaborators: name: Takeda Development Center Americas, Inc.
First posted: 2019-10-08
Enrollment: 53
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main aim is to check the long term side effects of a repeat treatment of darvadstrocel and to see if that treatment improves symptoms of Crohn's disease and complex perianal fistula. Participants will attend 8 clinic visits and will receive 1 treatment of darvadstrocel at the third visit. A magnetic resonance imaging (MRI) will be performed several times during the study.

Detailed description: The biological being tested in this study is called darvadstrocel (Alofisel). This study is examining the long-term safety and efficacy of a repeat dose of darvadstrocel in people who have Crohn's disease and complex perianal fistula.

The study will enroll approximately 50 patients. Participants will be assigned to one treatment group to receive:

• Darvadstrocel 120 million cells

All participants would be allowed to receive one repeat dose of darvadstrocel in the whole study. This multi-center trial will be conducted worldwide. The overall time to participate in this study is approximately 3 years. Participants will make multiple visits to the clinic.

Eligibility criteria: Inclusion Criteria:

1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
2. The participant signs and dates a written, ICF and any required privacy authorization before the initiation of any study procedures.
3. The participant is male or female and aged 18 years or older.
4. The participant has complex perianal fistula(s) with a maximum of 2 internal openings and a maximum of 3 external openings based on clinical assessment and a reading of a locally-performed contrast enhanced (gadolinium) pelvic MRI. Fistula(s) must have been draining for at least 6 weeks prior to baseline visit. A complex perianal fistula is defined as a fistula that meets 1 or more of the following criteria:

   1. High inter-sphincteric, high trans-sphincteric, extra-sphincteric or suprasphincteric.
   2. Presence of ≥2 external openings.
   3. Associated perianal abscess(es). Note: Abscesses that are larger than 2 cm in at least 2 dimensions on MRI must be confirmed to have been drained adequately by the surgeon during the preparation curettage in order to be eligible.
5. The participant has already received treatment with darvadstrocel for a complex perianal fistula at least 6 months prior to baseline visit for retreatment, and their physician has planned a repeat treatment administration for the original tract (full remission not obtained or relapse of fistula draining) or for a new complex perianal fistula tract.
6. The participant has controlled or mildly active Crohn's disease (CD) (defined as patient reported outcomes measure derived from CDAI patient reported outcome score-2 \[PRO-2\] score \<14).
7. A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use barrier method of contraception (e.g. condom with or without spermicide) from signing of informed consent and until 1 year after repeat administration.
8. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use a highly effective/effective method of contraception from signing of informed consent and until 1 year after repeat administration.

Exclusion Criteria:

1. The participant has lack of clinical response to prior treatment with darvadstrocel, where clinical response is defined as closure of at least 50% of all treated external fistula openings that were draining at baseline despite gentle finger compression or in the case of a unique fistula, a partial closure of the fistula.
2. The participant has a history of hypersensitivity or allergies to darvadstrocel or related compounds.
3. The participant has a history of hypersensitivity or allergies to penicillin or to aminoglycosides; Dulbecco modified eagle medium; bovine serum; local anesthetics or gadolinium.
4. The participant is currently participating in a double-blind clinical study with darvadstrocel. Participants participating in the ongoing INSPIRE registry (Alofisel-5003) study would need to withdraw from that study in order to enroll in this study.
5. The participant is currently receiving or has received any other investigational medicinal product (IMP) within the last 3 months or at least 5 times the respective elimination half-life time, whichever is longer, before signing the ICF.
6. The participant has known or suspected COVID-19 by the investigator within the past 2 months (additional testing may be performed at the discretion of the investigator). Positive antibody testing for COVID without other evidence of current or recent active infection does not exclude participation.

   a) Participants who were in screening at the time that COVID 19-related factors resulted in discontinuation may also be rescreened with approval of the sponsor or designee.
7. The participant has major alterations in any of the following laboratory tests:

   1. Serum creatinine levels \>1.5 times the upper limit of normal (ULN).
   2. Total bilirubin \>1.5 × ULN.
   3. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3.0 × ULN.
   4. Hemoglobin \<10.0 grams per deciliter (g/dL).
   5. Platelets \<75.0 × 10\^9 per liter (/L).
   6. Albumin \<3.0 g/dL.
8. The participant has an increased risk for a surgical procedure.
9. The participant has a known chronically active hepatopathy of any origin, including cirrhosis and participants with persistent positive hepatitis B surface antigen and quantitative hepatitis B virus polymerase chain reaction (PCR) or positive serology for hepatitis C virus (HCV) and quantitative HCV PCR within 6 months before the baseline visit.
10. If female, the participant is pregnant or breastfeeding, or intending to become pregnant before participating in this study, during the study, or intending to donate ova during such time period.
11. If male, the participant intends to donate sperm during this study.
12. The participant has a contraindication to MRI scan (e.g., due to the presence of pacemaker, hip replacement, severe claustrophobia, or renal insufficiency as defined by local clinical guidelines).
13. The participant has a contraindication to the anesthetic procedure.
14. The participant has severe rectal and/or anal stenosis that would make it impossible to follow the surgery procedure.
15. The participant has severe proctitis (rectal ulcers \>0.5 cm) that would make it impossible to follow the surgery procedure.
16. The participant has any prior invasive malignancy diagnosed within the last 3 years before baseline visit. Participants with basal cell carcinoma of the skin completely resected outside the perineal region can be included.
17. The participant has a current or recent (within 6 months before the baseline visit) history of severe, progressive, and/or uncontrolled hepatic, hematologic, gastrointestinal (other than CD), renal, endocrine, pulmonary, cardiac, neurologic, or psychiatric disease that may result in participant's increased risk from study participation and/or lack of compliance with study procedures.
18. The participant has had major surgery of the gastrointestinal tract within 6 months before baseline or any minor surgery of the gastrointestinal tract 3 months before baseline.
19. The participant had local major perianal surgery, and/or treatment with darvadstrocel within 6 months before baseline. The abscess drainage, cleaning surgery, or seton placement are not considered as "local major surgery" in this protocol.
20. The participant does not wish to or cannot comply with study procedures.

Primary outcomes:
measure: Percentage of Participants with at Least 1 Treatment-Emergent Adverse Event (TEAE)
timeFrame: From signing of informed consent form (ICF ) up to 156 weeks post-repeat administration
measure: Percentage of Participants with at Least 1 Treatment Emergent Serious Adverse Event (TESAE)
timeFrame: From signing of ICF up to 156 weeks post-repeat administration
measure: Number of Female Participants who are Pregnant
timeFrame: From administration of repeat dose up to 156 weeks post-repeat administration
measure: Percentage of Participants with Treatment Emergent Adverse Event of Special Interest (TEAESI)
timeFrame: From signing of ICF up to 156 weeks post-repeat administration
Secondary outcomes:
measure: Percentage of Participants who Achieve Combined Remission of Perianal Fistula(s)
timeFrame: At Week 24 and at Week 156 post-repeat darvadstrocel administration
measure: Percentage of Participants who Achieve Clinical Remission
timeFrame: At Weeks 6, 24, 52, 104, and 156 post-repeat darvadstrocel administration
measure: Percentage of Participants who Achieve Clinical Response
timeFrame: At Weeks 6, 24, 52, 104, and 156 post-repeat darvadstrocel administration
measure: Percentage of Participants with Relapse From Week 24 Combined Remission
timeFrame: From Week 24 to Week 156 post-repeat darvadstrocel administration
measure: Time to Relapse
timeFrame: From Week 24 to the Day of relapse post-repeat darvadstrocel administration
measure: Percentage of Participants with New Perianal Abscess in Treated Fistula
timeFrame: Up to Week 156 post-repeat darvadstrocel administration
measure: Change From Baseline in Score of Discharge and Pain Items of Perianal Disease Activity Index (PDAI) Score
timeFrame: Baseline to Weeks 6, 24, 52, 104, and 156 post-repeat darvadstrocel administration
Other outcomes:
Locations:
city: Wien
country: Austria
facility: Akh Wien
city: Horovice
country: Czechia
facility: NH Hospital a.s.
city: Prague
country: Czechia
facility: ISCARE a.s.
city: Nice cedex 03
country: France
facility: CHU de Nice - Hopital de l'Archet II - Gastro-Enterologie, Hepatologi
state: Alpes-Maritimes
city: Rennes
country: France
facility: CHRU Hopital de Pontchaillou - Maladies De L'Appareil Digesti
state: Ille-et-Vilaine
city: Lille
country: France
facility: CHRU de Lille - Hopital Claude Huriez - Gastroenterologie
state: Nord
city: AMIENS cedex 1
country: France
facility: CHU AMIENS PICARDIE Site SUD Hepato-Gastroenterology
state: Picardie
city: Pierre-Benite
country: France
facility: Centre Hospitalier Lyon Sud - Gastroenterology
state: Rhone
city: Paris
country: France
facility: Paris St. Joseph Hospital
city: Paris
country: France
facility: Groupe Hospitalier Diaconesses Croix Saint Simon
city: Dresden
country: Germany
facility: Klinikum Dresden, University Hospital Dresden
state: Sachsen
city: Luneburg
country: Germany
facility: Stadtisches Klinikum Luneburg
state: Schleswig-Holstein
city: Berlin
country: Germany
facility: Charite - Campus Benjamin Franklin
city: Berlin
country: Germany
facility: Krankenhaus Waldfriede
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization, Hadassah Medical Center, Ein-Karem
city: Petah Tikva
country: Israel
facility: Rabin Medical Center, Beilinson Hospital
city: Tel Aviv
country: Israel
facility: Tel Aviv Sourasky Medical Center
city: Tel Hashomer
country: Israel
facility: Chaim sheba Medical Center
city: Palma de Mallorca
country: Spain
facility: Hospital Universitario Son Espases
state: Baleares
city: Santa Cruz de Tenerife
country: Spain
facility: Hospital Universitario Nuestra Senora de la Candelaria
state: Canarias
city: Donostia
country: Spain
facility: H. Donostia
state: San Sebastian
city: Barcelona
country: Spain
facility: Hospital Universitario Vall d'Hebron
city: Barcelona
country: Spain
facility: Hospital Clinic de Barcelona
city: Barcelona
country: Spain
facility: Hospital Universitari de Bellvitge
city: Madrid
country: Spain
facility: Hospital Universitario Fundacion Jimenez Diaz
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
city: Pontevedra
country: Spain
facility: C.H.U. de Pontevedra
city: Valencia
country: Spain
facility: H.C.U. de Valencia
city: Valencia
country: Spain
facility: Hospital Universitari i Politecnic La Fe
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References: